Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03780543 · ClinicalTrials.gov registry record · Phase 2
A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients
A Phase 2 study, sponsored by Assembly Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT03780543: Clinical Trial Phase 2 study, sponsored by Assembly Biosciences.
NCT03780543 is a Phase 2 study that was terminated before completion, run by Assembly Biosciences. The registered enrollment target is 92 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03780543, a Phase 2 study, was terminated before completion, sponsored by Assembly Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
Open-label, extension study to evaluate the safety and efficacy of combination therapy and its effect on sustained viral response biomarkers.
Primary Outcome
To evaluate the potential for combination therapy with ABI-H0731+ NrtI to increase SVR rates in subjects who have chronic hepatitis B (CHB). To evaluate the proportion of subjects who meet the definition of SVR at 24 weeks off treatment, the SVR rate and corresponding 95% confidence interval will be presented for the overall population while on combination therapy. SVR is defined as sustained viral response with HBV DNA , LOQ (20 IU/mL) through off-treatment Week 24.
Interventions
- DRUG standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2021-04-26 |
| Phase | Phase 2 |
Why NCT03780543 stopped before completion
NCT03780543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 1 intervention - of which standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI) is the first listed.
NCT03780543 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03780543 about?
NCT03780543 is a clinical study titled "A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients". Open-label, extension study to evaluate the safety and efficacy of combination therapy and its effect on sustained viral response biomarkers.
What is the current status of trial NCT03780543?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2018-12-20. Estimated completion is 2021-04-26.
What interventions are being tested in trial NCT03780543?
The interventions under investigation include: standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI) (DRUG).
Who is sponsoring clinical trial NCT03780543?
This trial is sponsored by Assembly Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03780543's enrollment target sits among peer trials
92 767th of 2000 higher than 1,230 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI